[Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report]

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):550-3. doi: 10.3779/j.issn.1009-3419.2011.06.14.

[Article in Chinese]

Authors

Meiling Zhao¹, Haihong Yang, Jianxing He

Affiliation

¹ Department of Cardiothoracic Surgery, Guangzhou Institution of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, China.

PMID: 21645463
PMCID: PMC5999889
DOI: 10.3779/j.issn.1009-3419.2011.06.14

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / pathology*
Carcinoma, Non-Small-Cell Lung / physiopathology
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives*
Deoxycytidine / therapeutic use
Drug Resistance, Neoplasm
Female
Gemcitabine
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Lung Neoplasms / pathology*
Lung Neoplasms / physiopathology
Ribonucleoside Diphosphate Reductase
Tumor Suppressor Proteins / metabolism

Substances

Antineoplastic Agents
Tumor Suppressor Proteins
Deoxycytidine
RRM1 protein, human
Ribonucleoside Diphosphate Reductase
Gemcitabine